AD vaccines: Conclusions and future directions

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 2, 2009, Pages 160-166

  Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; PLACEBO; POLYSORBATE 80; QS 21; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTIGENICITY; DRUG DESIGN; DRUG FORMULATION; DRUG TARGETING; EARLY INTERVENTION; ENCEPHALITIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; RISK BENEFIT ANALYSIS; TH1 CELL; TREATMENT PLANNING; VACCINATION; VACCINE PRODUCTION; VASCULAR AMYLOIDOSIS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SENILE PLAQUE; STANDARD;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; CEREBRAL AMYLOID ANGIOPATHY; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; IMMUNOTHERAPY, ACTIVE; NEUROFIBRILLARY TANGLES; SENILE PLAQUES;

EID: 67649662393     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787847289     Document Type: Article

References (61)

1. Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H.M. Forecasting the global burden of Alzheimer's disease. Alz. Dementia, 2007, 3, 186-91.
2. Rafii, M.S.; Aisen, P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med., 2009, 7, 7.
3. Wisniewski, T.; Frangione, B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathology, 2005, 15, 72-7.
4. Bayer, A.J.; Bullock, R.; Jones, R.W.; Wilkinson, D.; Paterson, K.R.; Jenkins, L.; Millais, S.B.; Donoghue, S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology, 2005, 64, 94-101.
5. Pride, M.; Seubert, P.; Grundman, M.; Hagen, M.; Eldridge, J.; Black, R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis., 2008, 5, 194-6.
6. Wisniewski, T. Practice point commentary on "Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial". Nat. Clin. Pract. Neurol., 2005, 1, 84-5.
7. Boche, D.; Nicoll, J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol., 2008, 18, 267-78.
8. Bombois, S.; Maurage, C.A.; Gompel, M.; Deramecourt, V.; kowiak-Cordoliani, M.A.; Black, R.S.; Lavielle, R.; Delacourte, A.; Pasquier, F. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol., 2007, 64, 583-7.
9. Ferrer, I.; Boada, R.M.; Sanchez Guerra, M.L.; Rey, M.J.; Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 2004, 14, 11-20.
10. Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; Seubert, P.; Games, D.; Kirby, L.; Schenk, D. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64, 129-31.
11. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2005, 9, 448-52.
12. Nicoll, J.A.; Barton, E.; Boche, D.; Neal, J.W.; Ferrer, I.; Thompson, P.; Vlachouli, C.; Wilkinson, D.; Bayer, A.; Games, D.; Seubert, P.; Schenk, D.; Holmes, C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol., 2006, 65, 1040-8.
13. Sadowski, M.; Wisniewski, T. Disease modifying approaches for Alzheimer's pathology. Curr. Pharm. Des., 2007, 13, 1943-54.
14. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Boada Rovira, M.; Forette, F.; Orgogozo, J.M. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial. Neurology, 2005, 64, 1553-62.
15. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A.R. Long term effects of Aβ42 immunization in Alzheimer's disease: immune response, plaque removal and clinical function. Lancet, 2008, 372, 216-23.
16. Price, J.L.; Morris, J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol., 1999, 45, 358-68.
17. Gotz, J.; Chen, F.; van, D.J.; Nitsch, R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science, 2001, 293, 1491-5.
18. Knopman, D.S.; Parisi, J.E.; Salviati, A.; Floriach-Robert, M.; Boeve, B.F.; Ivnik, R.J.; Smith, G.E.; Dickson, D.W.; Johnson, K.A.; Petersen, L.E.; McDonald, W.C.; Braak, H.; Petersen, R.C. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol., 2003, 62, 1087-95.
19. Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; LaFerla, F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004, 43, 321-32.
20. Fagan, A.M.; Roe, C.M.; Xiong, C.; Mintun, M.A.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol., 2007, 64, 343-9.
21. Mosconi, L.; Mistur, R.; Switalski, R.; Tsui, W.H.; Glodzik, L.; Li, Y.; Pirraglia, E.; De, S.S.; Reisberg, B.; Wisniewski, T.; De Leon, M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging, 2009, in Press.
22. Sigurdsson, E.M.; Wadghiri, Y.Z.; Mosconi, L.; Blind, J.A.; Knudsen, E.; Asuni, A.; Tsui, W.H.; Sadowski, M.; Turnbull, D.; de Leon, M.; Wisniewski, T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging, 2008, 29, 836-77.
23. Scholtzova, H.; Wadghiri, Y.Z.; Douadi, M.; Sigurdsson, E.M.; Li, Y.; Quartermain, D.; Banerjee, P.; Wisniewski, T. A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown by micro-magnetic resonance imaging. J. Neurosci. Res., 2008, 86, 2784-91.
24. Rowe, C.C.; Ng, S.; Ackermann, U.; Gong, S.J.; Pike, K.; Savage, G.; Cowie, T.F.; Dickinson, K.L.; Maruff, P.; Darby, D.; Smith, C.; Woodward, M.; Merory, J.; Tochon-Danguy, H.; O'Keefe, G.; Klunk, W.E.; Mathis, C.A.; Price, J.C.; Masters, C.L.; Villemagne, V.L. Imaging beta-amyloid burden in aging and dementia. Neurology, 2007, 68, 1718-25.
25. Forsberg, A.; Engler, H.; Almkvist, O.; Blomquist, G.; Hagman, G.; Wall, A.; Ringheim, A.; Langstrom, B.; Nordberg, A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging, 2008, 29, 1456-65.
26. Gandy, S.; DeMattos, R.B.; Lemere, C.A.; Heppner, F.L.; Leverone, J.; Aguzzi, A.; Ershler, W.B.; Dai, J.; Fraser, P.; St George HP.; Holtzman, D.M.; Walker, L.C.; Keller, E.T. Alzheimer's Aβ vaccination of rhesus monkeys (Macaca mulatta). Alzheimer's Dis. Assoc. Disord., 2004, 18, 44-6.
27. Lemere, C.A.; Beierschmitt, A.; Iglesias, M.; Spooner, E.T.; Bloom, J.K.; Leverone, J.F.; Zheng, J.B.; Seabrook, T.J.; Louard, D.; Li, D.; Selkoe, D.J.; Palmour, R.M.; Ervin, F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol., 2004, 165, 283-97.
28. Trouche, S.G.; Asuni, A.; Rouland, S.; Wisniewski, T.; Frangione, B.; Verdier, J.M.; Sigurdsson, E.M.; Mestre-Frances, N. Antibody response and plasma Aβ1-40 in young Microcebus Murinus primates immunized with Aβ1-42 and its derivatives. Vaccine, 2009, 27, 957-64.
29. Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; Nistor, M.; Christie, L.A.; Milton, S.; Glabe, C.; Barrett, E.; Cribbs, D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci., 2008, 28, 3555-66.
30. Cribbs, D.H.; Ghochikyan, A.; Vasilevko, V.; Tran, M.; Petrushina, I.; Sadzikava, N.; Babikyan, D.; Kesslak, P.; Kieber-Emmons, T.; Cotman, C.W.; Agadjanyan, M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol., 2003, 15, 505-14.
31. Maier, M.; Seabrook, T.J.; Lazo, N.D.; Jiang, L.; Das, P.; Janus, C.; Lemere, C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci., 2006, 26, 4717-28.
32. Sigurdsson, E.M.; Scholtzova, H.; Mehta, P.; Frangione, B.; Wisniewski, T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol., 2001, 159, 439-47.
33. Sigurdsson, E.M.; Knudsen, E.L.; Asuni, A.; Sage, D.; Goni, F.; Quartermain, D.; Frangione, B.; Wisniewski, T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J. Neurosci., 2004, 24, 6277-82.
34. Agadjanyan, M.G.; Ghochikyan, A.; Petrushina, I.; Vasilevko, V.; Movsesyan, N.; Mkrtichyan, M.; Saing, T.; Cribbs, D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol., 2005, 174, 1580-6.
35. Zamora, E.; Handisurya, A.; Shafti-Keramat, S.; Borchelt, D.; Rudow, G.; Conant, K.; Cox, C.; Troncoso, J.C.; Kirnbauer, R. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J. Immunol., 2006, 177, 2662-70.
36. Chackerian, B.; Rangel, M.; Hunter, Z.; Peabody, D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine, 2006, 24, 6321-31.
37. Jennings, G.T.; Bachmann, M.F. The coming of age of virus-like particle vaccines. Biol. Chem., 2008, 389, 521-36.
38. Movsesyan, N.; Ghochikyan, A.; Mkrtichyan, M.; Petrushina, I.; Davtyan, H.; Olkhanud, P.B.; Head, E.; Biragyn, A.; Cribbs, D.H.; Agadjanyan, M.G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE, 2008, 3, e2124.
39. Asuni, A.; Boutajangout, A.; Scholtzova, H.; Knudsen, E.; Li, Y.; Quartermain, D.; Frangione, B.; Wisniewski, T.; Sigurdsson, E.M. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur. J. Neurosci., 2006, 24, 2530-42.
40. Lemere, C.A.; Spooner, E.T.; Leverone, J.F.; Mori, C.; Clements, J.D. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol. Aging, 2002, 23, 991-1000.
41. Seabrook, T.J.; Thomas, K.; Jiang, L.; Bloom, J.; Spooner, E.; Maier, M.; Bitan, G.; Lemere, C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging, 2006.
42. Nikolic, W.V.; Bai, Y.; Obregon, D.; Hou, H.; Mori, T.; Zeng, J.; Ehrhart, J.; Shytle, R.D.; Giunta, B.; Morgan, D.; Town, T.; Tan, J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl. Acad. Sci. USA, 2007, 104, 2507-12.
43. Frackowiak, J.; Wisniewski, H.M.; Wegiel, J.; Merz, G.S.; Iqbal, K.; Wang, K.C. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol., 1992, 84, 225-33.
44. Jucker, M.; Heppner, F.L. Cerebral and peripheral amyloid phagocytes - an old liaison with a new twist. Neuron, 2008, 59, 8-10.
45. Butovsky, O.; Kunis, G.; Koronyo-Hamaoui, M.; Schwartz, M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci., 2007, 26, 413-6.
46. El, K.J.; Toft, M.; Hickman, S.E.; Means, T.K.; Terada, K.; Geula, C.; Luster, A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med., 2007, 13, 432-8.
47. Scholtzova, H.; Kascsak, R.J.; Bates, K.A.; Boutajangout, A.; Kerr, D.J.; Meeker, H.C.; Mehta, P.D.; Spinner, D.S.; Wisniewski, T. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J. Neurosci., 2009, 29, 1846-54.
48. Obregon, D.; Hou, H.; Bai, Y.; Nikolic, W.V.; Mori, T.; Luo, D.; Zeng, J.; Ehrhart, J.; Fernandez, F.; Morgan, D.; Giunta, B.; Town, T.; Tan, J. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol. Dis., 2008, 29, 336-53.
49. Town, T.; Laouar, Y.; Pittenger, C.; Mori, T.; Szekely, C.A.; Tan, J.; Duman, R.S.; Flavell, R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med., 2008, 14, 681-7.
50. Glabe, C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem., 2008, 283, 29639-43.
51. Klybin, I.; Betts, V.; Blennow, K.; Zetterberg, H.; Wallin, A.; Lemere, C.A.; Cullen, W.K.; Welzel, A.; Peng, Y.; Wisniewski, T.; Selkoe, D.J.; Anwyl, R.; Walsh, D.M.; Rowan, M.J. Aβ dimer-containing human cerebrospinal fluid disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci., 2008, 28, 4231-7.
52. Lee, E.B.; Leng, L.Z.; Zhang, B.; Kwong, L.; Trojanowski, J.Q.; Abel, T.; Lee, V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem., 2006, 281, 4292-9.
53. Moretto, N.; Bolchi, A.; Rivetti, C.; Imbimbo, B.P.; Villetti, G.; Pietrini, V.; Polonelli, L.; Del, S.S.; Smith, K.M.; Ferrante, R.J.; Ottonello, S. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J. Biol. Chem., 2007, 282, 11436-45.
54. Mamikonyan, G.; Necula, M.; Mkrtichyan, M.; Ghochikyan, A.; Petrushina, I.; Movsesyan, N.; Mina, E.; Kiyatkin, A.; Glabe, C.G.; Cribbs, D.H.; Agadjanyan, M.G. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem., 2007, 282, 22376-86.
55. Origlia, N.; Capsoni, S.; Cattaneo, A.; Fang, F.; Arancio, O.; Yan, S.D.; Domenici, L. Abeta-dependent inhibition of LTP in different intra-cortical circuits of the visual cortex: the role of RAGE. J. Alzheimers. Dis., 2009.
56. Jellinger, K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm., 2002, 109, 813-36.
57. Zhang-Nunes, S.X.; Maat-Schieman, M.L.; Van Duinen, S.G.; Roos, R.A.; Frosch, M.P.; Greenberg, S.M. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol., 2006, 16, 30-9.
58. Patton, R.L.; Kalback, W.M.; Esh, C.L.; Kokjohn, T.A.; Van Vickle, G.D.; Luehrs, D.C.; Kuo, Y.M.; Lopez, J.; Brune, D.; Ferrer, I.; Masliah, E.; Newel, A.J.; Beach, T.G.; Castano, E.M.; Roher, A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol., 2006, 169, 1048-63.
59. Asuni, A.A.; Boutajangout, A.; Quartermain, D.; Sigurdsson, E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci., 2007, 27, 9115-29.
60. Wisniewski, T.; Sigurdsson, E.M. Therapeutic approaches for prion and Alzheimer's diseases. FEBS J., 2007, 274, 3784-98.
61. Goni, F.; Chabalgoity, J.A.; Prelli, F.; Schreiber, F.; Chung, E.; Kascsak, R.; Kascsak, R.; Brown, D.R.; Sigurdsson, E.M.; Wisniewski, T. High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. Neuroscience, 2008, 153, 679-86.